09 Nov 20 | All | Formycon, Bioeq | Formycon and Bioeq announces they have commenced dosing in Ph III trials of FYB202 (proposed ustekinumab biosimilar) in patients with moderate to severe plaque psoriasis.

28 Oct 20 | All | Amgen | In its Q3 2020 financial results, Amg...

September 10, 2020

10 Sep 2020 | All | All |  Neurology Advisor reports a new study indicates that natalizumab may be more effective than fingolimod or BRACETD in reducing relapses in patients with relapsing-remitting multiple sclerosis.

21 Nov 2019 | All | Polpharma/Sandoz | Polphar...

Please reload

Biosimilars bulletin 

November 9, 2020

Please reload

Search by tags